Incyte wipes out late-phase epacadostat program after pivotal failure of Keytruda combination

Incyte wipes out late-phase epacadostat program after pivotal failure of Keytruda combination

Source: 
Fierce Biotech
snippet: 

Incyte has taken an ax to its suite of late-phase epacadostat trials after digesting the implications of last month’s pivotal study blowup. The cull sees Incyte downgrade two pivotal epacadostat-Keytruda trials to phase 2 studies and back away from six other late-stage tests of its IDO inhibitor.